Replies to post #1485 on Precious Metals

[gfp927z]

Blade, Thanks. The volatility of these bio stocks is what gets me. I have trouble not taking profits when they appear, even though that could mean missing out on a great longer term stock.

I was wondering if there are some general ground rules that you use, for example selling 1/2 of a position if you get a double? And do you set a stop loss under your positions? Bio stocks mainly move on the clinical progress and news flow, and you look for well funded companies, which is a great parameter, but do you have certain hard/fast rules, or is it a more flexible approach? Any bio sub-sectors that you always avoid, etc?

Thanks for any insights.

[gfp927z]

Blade, Just curious if you see this as possibly a good buying opportunity for FSTX, with the stock trading down at/near the $7 stock offering price.
Thanks.

Looks like this financing more than doubles the shares outstanding, but that is coming off of tiny base, and the company should now have plenty of cash for a while. Thanks for any insights.

[bladerunner1717]

CRIS jumps (65%) after showing impressive results in hematological cancers


Curis jumps after blood cancer trial indicates impressive results

May 12, 2021 11:29 AM ETCuris, Inc. (CRIS)By: Dulan Lokuwithana, SA News

Curis (CRIS +58.7%) is surging after announcing updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).

As of data cut off on February 8, 2021, in 15 patients (8 MDS and 7 AML), four objective responses were recorded with signs of hematologic recovery.

The included one complete response (CR), one complete remission with incomplete hematologic recovery (CRi) with negative minimal residual disease, and two bone marrow CRs, the company said.
The two abstracts with updated data have been accepted for oral and poster presentation at the upcoming European Hematology Association 2021 Virtual Congress (EHA).

CA-4948 is an IRAK4 kinase inhibitor that is believed to be involved in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways.
TLR and IL-1R pathways are frequently dysregulated in patients with AML and MDS.

Rigel Pharmaceuticals (RIGL +16.5%) is also rising in conjunction. The company has a partnership with BerGenBio for BGB324 (bemcentinib), a first-in-class selective AXL kinase inhibitor.

BGB324 is undergoing Phase 1/2 studies as a single agent for relapsed AML and MDS. and in combination with erlotinib (Tarceva) in advanced (EGFR-positive) non-small-cell lung carcinoma.


Bladerunner